Business Description
Mirum Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
08D.Germany
•
MIRM.Mexico
•
MIRM.USA
Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 55.07 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.24 | |||||
| Beneish M-Score | 1.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.38 | |||||
| 9-Day RSI | 35.97 | |||||
| 14-Day RSI | 38.91 | |||||
| 6-1 Month Momentum % | 12.48 | |||||
| 12-1 Month Momentum % | 35.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.26 | |||||
| Quick Ratio | 3.16 | |||||
| Cash Ratio | 2.77 | |||||
| Days Inventory | 187.29 | |||||
| Days Sales Outstanding | 79.38 | |||||
| Days Payable | 481.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.15 | |||||
| Operating Margin % | -396.16 | |||||
| Net Margin % | -137.85 | |||||
| ROE % | -53.96 | |||||
| ROA % | -19.62 | |||||
| ROIC % | -134.61 | |||||
| ROC (Joel Greenblatt) % | -1672.54 | |||||
| ROCE % | -18.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 17.12 | |||||
| PB Ratio | 6.17 | |||||
| Price-to-Tangible-Book | 10.64 | |||||
| EV-to-EBIT | -15.36 | |||||
| EV-to-EBITDA | -16.09 | |||||
| EV-to-Revenue | 17.01 | |||||
| EV-to-Forward-Revenue | 4.11 | |||||
| EV-to-FCF | -4.86 | |||||
| Earnings Yield (Greenblatt) % | -6.51 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MIRM
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 38.514 | ||
| EPS (TTM) ($) | -1.678 | ||
| Beta | 1.41 | ||
| Volatility % | 58.15 | ||
| 14-Day RSI | 38.91 | ||
| 14-Day ATR ($) | 1.427834 | ||
| 20-Day SMA ($) | 23.372 | ||
| 12-1 Month Momentum % | 35.19 | ||
| 52-Week Range ($) | 12.82 - 30.545 | ||
| Shares Outstanding (Mil) | 36.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mirum Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mirum Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.